The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: A test tube labelled with the vaccine is seen in front of AstraZeneca logo in this illustration taken (Reuters) - ...

AstraZeneca has completed the sell-off of another mature product, hiving off its Atacand cardiovascular franchise to Cheplapharm as it continues to slim down and invest in its pipeline. The German ...

The total value of all payments for the Atacand brand is $400m AstraZeneca has completed the divestment of the rights to its heart failure and hypertension brand Atacand (candesartan cilexetil) in ...

Cheplapharm will pay AstraZeneca a total of $400m in non-contingent consideration, of which the present value will be recognised as Other Operating Income upon completion of the transaction, ...

AstraZeneca is selling off European commercial rights to its high blood pressure drug Atacand to German biotech Cheplapharm, securing $200 million for “company’s new wave of medicines”. The deal, ...

AstraZeneca is selling rights to its heart failure and hypertension brand Atacand in Europe, in a move that it says will expand its commercial potential in 28 countries. AstraZeneca is selling rights ...